CIK 0001472012 · Non-accelerated filer
Immunome Inc.
Sign in to watch- Ticker
- IMNM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770694340
- Phone
- 610-321-3700
- Business address
- 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL, WA, 98011
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $334,224
- in 1 filing, $334K under 10b5-1 plans
Net −$334,224. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 56 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-20 | Horn Kinney CHIEF BUSINESS OFFICER | Grant or award · Stock option (right to buy) | +300,000 | 300,000 | ||
| 2024-01-31 | Rosett Max EVP, OPERATIONS & INTERIM CFO | Grant or award · Stock option (right to buy) | +175,000 | 175,000 | ||
| 2024-01-31 | Stoneman Sandra G. CHIEF LEGAL OFFICER & GC | Grant or award · Stock option (right to buy) | +200,000 | 200,000 | ||
| 2024-01-02 | SCHAFER CAROL Director | Grant or award · Stock option (right to buy) | +32,934 | 32,934 | ||
| 2023-12-13 | Roberts Phil Noland Chief Technology Officer | Grant or award · Stock option (right to buy) | +275,000 | 275,000 | ||
| 2023-12-01 | Higgins Jack Chief Scientific Officer | Grant or award · Stock option (right to buy) | +200,000 | 200,000 | ||
| 2023-11-07 | BIENAIME JEAN JACQUES Director | Grant or award · Stock option (right to buy) | +40,696 | 40,696 | ||
| 2023-10-27 | Barchas Isaac Director | Grant or award · Stock option (right to buy) | +41,538 | 41,538 | ||
| 2023-10-27 | Boylan James P Director | Grant or award · Stock option (right to buy) | +41,538 | 41,538 | ||
| 2023-10-27 | Lechleider Robert Chief Medical Officer | Grant or award · Stock option (right to buy) | +400,000 | 400,000 | ||
| 2023-10-02 | SIEGALL CLAY B President and CEO | Purchase | +169,204 | $5.91 | $1000K | 319,636 |
| 2023-10-02 | Turner Bruce Chief Strategy Officer | Purchase | +42,300 | $5.91 | $250K | 42,300 |
| 2023-10-02 | PRENDERGAST FRANKLYN G Director | Grant or award | +60,840 | 60,840 | ||
| 2023-10-02 | PRENDERGAST FRANKLYN G Director | Grant or award · Stock Option (Right to Buy) | +137,725 | $1.35 | $186K | 137,725 |
| 2023-10-02 | RAPP MICHAEL Director | Grant or award | +253,806 | $5.91 | $1.5M | 1,071,172 |
| 2023-06-08 | RAPP MICHAEL Director | Grant or award · Stock Option (Right to Buy) | +6,500 | 6,500 | ||
| 2023-06-08 | Stoneman Sandra G. General Counsel and CLO | Grant or award · Stock Option (Right to Buy) | +56,000 | 56,000 | ||
| 2023-06-08 | Roche Corleen M. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +58,000 | 58,000 | ||
| 2023-06-08 | ROBINSON MATTHEW K Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +58,000 | 58,000 |
Page 8 of 8 · 159 trades